Benzgalantamine, sold under the brand name Zunveyl, is a medication used for the treatment of mild to moderate dementia of the Alzheimer's type.[1] It is a cholinesterase inhibitor.[1] Benzgalantamine is a prodrug of galantamine.[1]
![]() | |
Clinical data | |
---|---|
Trade names | Zunveyl |
Other names | ALPHA-1062 |
AHFS/Drugs.com | Zunveyl |
License data | |
Routes of administration | By mouth |
Drug class | Cholinesterase inhibitor |
ATC code |
|
Legal status | |
Legal status | |
Identifiers | |
CAS Number | |
UNII | |
KEGG | |
ChEMBL | |
Chemical and physical data | |
Formula | C24H25NO4 |
Molar mass | 391.467 g·mol−1 |
3D model (JSmol) | |
| |
|
The most common side effects include nausea, vomiting, diarrhea, dizziness, headache, and decreased appetite.[1]
Benzgalantamine was approved for medical use in the United States in July 2024.[1][2][3]
Medical uses
editBenzgalantamine is indicated for the treatment of mild to moderate dementia of the Alzheimer's type in adults.[1][2]
Side effects
editThe most common side effects include nausea, vomiting, diarrhea, dizziness, headache, and decreased appetite.[1]
Society and culture
editLegal status
editBenzgalantamine was approved for medical use in the United States in July 2024.[1][2]
Names
editBenzgalantamine is the international nonproprietary name.[4]
References
edit- ^ a b c d e f g h i "Zunveyl- benzgalantamine tablet, delayed release". DailyMed. 8 August 2024. Retrieved 15 August 2024.
- ^ a b c https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2024/218549Orig1s000ltr.pdf
- ^ "Alpha Cognition's Oral Therapy Zunveyl Receives FDA Approval to Treat Alzheimer's Disease" (Press release). Alpha Cognition. 29 July 2024. Archived from the original on 4 August 2024. Retrieved 4 August 2024 – via Business Wire.
- ^ World Health Organization (2022). "International nonproprietary names for pharmaceutical substances (INN): recommended INN: list 88". WHO Drug Information. 36 (3). hdl:10665/363551.
External links
edit- "Benzgalantamine (Code C188656)". NCI Thesaurus.